

Viswanath Devanarayan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12093592/publications.pdf>

Version: 2024-02-01

34
papers

4,830
citations

279798

23
h-index

377865

34
g-index

40
all docs

40
docs citations

40
times ranked

6662
citing authors

#	ARTICLE	IF	CITATIONS
1	Best practices for the development and fit-for-purpose validation of biomarker methods: a conference report. AAPS Open, 2022, 8, .	1.3	0
2	Comparison of Titer and Signal to Noise (S/N) for Determination of Anti-drug Antibody Magnitude Using Clinical Data from an Industry Consortium. AAPS Journal, 2022, 24, .	4.4	5
3	Serum Phosphatidylethanolamine and Lysophosphatidylethanolamine Levels Differentiate Alzheimer's Disease from Controls and Predict Progression from Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2021, 80, 311-319.	2.6	27
4	Recommendations for the Development and Validation of Immunogenicity Assays in Support of Biosimilar Programs. AAPS Journal, 2020, 22, 7.	4.4	17
5	Are Lessons Learned in Setting Cut Points for Detection of Anti-Drug Antibodies Also Useful in Serology Assays for Robust Detection of SARS-CoV-2 Reactive Antibodies?. AAPS Journal, 2020, 22, 127.	4.4	3
6	Hearing Loss in Alzheimer's Disease Is Associated with Altered Serum Lipidomic Biomarker Profiles. Cells, 2020, 9, 2556.	4.1	14
7	Report on the AAPS Immunogenicity Guidance Forum. AAPS Journal, 2019, 21, 55.	4.4	14
8	Identification of a Simple and Novel Cut-Point Based Cerebrospinal Fluid and MRI Signature for Predicting Alzheimer's Disease Progression that Reinforces the 2018 NIA-AA Research Framework. Journal of Alzheimer's Disease, 2019, 68, 537-550.	2.6	11
9	VGF in Cerebrospinal Fluid Combined With Conventional Biomarkers Enhances Prediction of Conversion From MCI to AD. Alzheimer Disease and Associated Disorders, 2019, 33, 307-314.	1.3	24
10	Patient subgroup identification for clinical drug development. Statistics in Medicine, 2017, 36, 1414-1428.	1.6	42
11	Recommendations for Systematic Statistical Computation of Immunogenicity Cut Points. AAPS Journal, 2017, 19, 1487-1498.	4.4	62
12	A multivariate predictive modeling approach reveals a novel CSF peptide signature for both Alzheimer's Disease state classification and for predicting future disease progression. PLoS ONE, 2017, 12, e0182098.	2.5	40
13	Big data to smart data in Alzheimer's disease: The brain health modeling initiative to foster actionable knowledge. Alzheimer's and Dementia, 2016, 12, 1014-1021.	0.8	65
14	Recommendations for Use and Fit-for-Purpose Validation of Biomarker Multiplex Ligand Binding Assays in Drug Development. AAPS Journal, 2016, 18, 1-14.	4.4	71
15	A PRIM approach to predictive signature development for patient stratification. Statistics in Medicine, 2015, 34, 317-342.	1.6	40
16	2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 3) Tj ETQq0,0,0 rgBT /Overlock 1	1.5	64
17	Comparison of RNA-seq and microarray-based models for clinical endpoint prediction. Genome Biology, 2015, 16, 133.	8.8	325
18	Randomized Phase II Study of Carboplatin and Paclitaxel With Either Linifanib or Placebo for Advanced Nonsquamous Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 2015, 33, 433-441.	1.6	45

#	ARTICLE	IF	CITATIONS
19	Recommendations for adaptation and validation of commercial kits for biomarker quantification in drug development. <i>Bioanalysis</i> , 2015, 7, 229-242.	1.5	39
20	Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanib. <i>Lung Cancer</i> , 2015, 90, 296-301.	2.0	12
21	The concordance between RNA-seq and microarray data depends on chemical treatment and transcript abundance. <i>Nature Biotechnology</i> , 2014, 32, 926-932.	17.5	420
22	Evaluation of Plasma Proteomic Data for Alzheimer Disease State Classification and for the Prediction of Progression From Mild Cognitive Impairment to Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2013, 27, 233-243.	1.3	53
23	Cerebrospinal Fluid Cytokine Dynamics Differ Between Alzheimer Disease Patients and Elderly Controls. <i>Alzheimer Disease and Associated Disorders</i> , 2012, 26, 322-328.	1.3	38
24	Screening for New Biomarkers for Subcortical Vascular Dementia and Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2011, 1, 31-42.	1.3	35
25	Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011, 55, 878-888.	2.8	119
26	Derivation of a New ADAS-cog Composite Using Tree-based Multivariate Analysis. <i>Alzheimer Disease and Associated Disorders</i> , 2011, 25, 73-84.	1.3	57
27	The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. <i>Nature Biotechnology</i> , 2010, 28, 827-838.	17.5	795
28	Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2008, 48, 1267-1281.	2.8	519
29	Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. <i>Journal of Immunological Methods</i> , 2008, 333, 1-9.	1.4	326
30	Confirmatory reanalysis of incurred bioanalytical samples. <i>AAPS Journal</i> , 2007, 9, E336-E343.	4.4	133
31	Optimization of analytical and pre-analytical variables associated with an ex vivo cytokine secretion assay. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2006, 41, 189-195.	2.8	17
32	Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement. <i>Pharmaceutical Research</i> , 2006, 23, 312-328.	3.5	684
33	Development, validation, and implementation of a multiplex immunoassay for the simultaneous determination of five cytokines in human serum. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2005, 36, 1037-1044.	2.8	118
34	Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. <i>Journal of Immunological Methods</i> , 2004, 289, 1-16.	1.4	576